Micrornas in neurodegenerative disorders

Abstract

Provided herein are methods of treating a neurodegenerative disorder such as Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS) that include administering to a subject at least one inhibitory nucleic acid that decreases the level or activity of microRNA hsa-miR-155.

Listing of claims: 
     
         1 .- 39 . (canceled) 
     
     
         40 . A method of treating amyotrophic lateral sclerosis (ALS) in a subject, the method comprising administering to the subject an inhibitory nucleic acid comprising a sequence that is complementary to a contiguous sequence of at least 7 nucleotides present in microRNA hsa-miR-155. 
     
     
         41 . The method of  claim 40 , wherein the at least one inhibitory nucleic acid is an antagomir. 
     
     
         42 . The method of  claim 41 , wherein the antagomir has a sequence of SEQ ID NO: 262. 
     
     
         43 . The method of  claim 40 , wherein the at least one inhibitory nucleic acid is an antisense oligonucleotide. 
     
     
         44 . The method of  claim 40 , wherein the at least one inhibitory nucleic acid is a ribozyme. 
     
     
         45 . The method of  claim 40 , wherein the at least one inhibitory nucleic acid is injected into the cerebrospinal fluid of a subject. 
     
     
         46 . The method of  claim 45 , wherein the injection is intracranial injection. 
     
     
         47 . The method of  claim 45 , wherein the injection is intrathecal injection. 
     
     
         48 . The method of  claim 40 , wherein the at least one inhibitory nucleic acid is complexed with one or more cationic polymers and/or cationic lipids.